・ ® National Hair loss National Hair loss Medical Aesthetics Medical Aesthetics Education Course President Carly Klein | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------|---------|-------|-------|-------|-------|-------| | | | | | | | | | leading cause of | | | | | | | | Alopecia is Genetics | | | | | | | | While hair loss is a common affliction for both men and women, there are two underlying ...

On Going Research Study Demonstrates Reversal of Hair Thinning and Inflammation with Elevai Exosomes™. Ongoing Research to Combine Exosome and Mitochondrial Technology for Enhanced Scalp and Hair Vitality. NEWPORT BEACH, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, today announced data results from an on-going research study conducted in partnership with Carly Klein, President of the National Hair Loss Medi ...

"One of the Biggest Innovations in Hair Loss We've Seen in Twenty-Five Years" - BosleyMD® Teams With Start-up Yuva Biosciences in National Launch of Breakthrough Technology1 Elevai Labs and Yuva Biosciences Join Forces for Breakthrough in Hair and Scalp Care Technology NEWPORT BEACH, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics announces the filing of two innovative patents in collaboration with Yuva Bioscien ...

NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance. The data, pending peer review, from the clinical study was internally reviewed by the Company, and the results show Elevai enfinity™ to be safe and tolerable with significant improvement noted across many aspects of skin appearance. Elev ...

Preliminary data from the research study in partnership with Dalhousie University demonstrates that Elevai's hUMSC derived exosomes ("ELEVAI exosomes™") contain over 800 proteins that are associated with wound healing, immunomodulation and remodeling of the skin's extracellular matrix ("ECM"). ELEVAI exosomes™ protein profile detected as part of this study was statistically significant and notably enriched compared to 54 previously published sets of exosome protein data. Data implies ELEVAI exosomes™ may be ...

NEWPORT BEACH, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update. Financial Results for the Three and Six Months Ended June 30, 2024 Revenue increased to $605,529 for the three months ended June 30, 2024, and $1,220,092 for the six months ended June 30, 2024, an increase of 91.3% and 165.6% respectively year- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41875 | --- | --- | --- | |-------------------------------------------------------|------------------------------------------------------------------------------- ...

Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme. Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator. Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. "Dr. Shirihai is recognized ...

Orian Shirihai, MD, PhD, is currently a Professor of Medicine at the University of California, Los Angeles (UCLA) where he serves as Director of the UCLA Metabolism Research Theme. The Shirihai laboratory focuses on mitochondrial structure, function and quality control, making key contributions to mitochondrial biology including the discovery of the life cycle of the mitochondria and the relationship between mitochondrial architecture and nutrient utilization in metabolic diseases. Another focus of the Shir ...

· ® NEXTGENERATION SKIN&SCALPREJUVENATION: STEM CELL EXOSOMES + MITOCHONDRIAL BIOGENESIS TECHNOLOGY DISCOVERED USING AI 2 Jordan R. Plews, PhD Biochemical Engineer & Stem Cell Scientist. Academic research completed at University College London, University of Sheffield, and Stanford University. AGSTANT CONTINUES COLLEGE 3 Cofounder of ELEVAI Labs Inc. (Nasdaq: ELAB) CEO of ELEVAI Skincare Inc. Experience with human stem cells, molecular biology, single cell genomics, proteomics, RNA analysis, as well as cell ...